Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.

Chari, Ajai Vogl, Dan T Gavriatopoulou, Maria Nooka, Ajay K Yee, Andrew J Huff, Carol A Moreau, Philippe Dingli, David Cole, Craig Lonial, Sagar Dimopoulos, Meletios Stewart, A Keith Richter, Joshua Vij, Ravi Tuchman, Sascha Raab, Marc S Weisel, Katja C Delforge, Michel Cornell, Robert F Kaminetzky, David Hoffman, James E Costa, Luciano J Parker, Terri L Levy, Moshe Schreder, Martin Meuleman, Nathalie Frenzel, Laurent Mohty, Mohamad Choquet, Sylvain Schiller, Gary Comenzo, Raymond L Engelhardt, Monika Illmer, Thomas Vlummens, Philip Doyen, Chantal [UCL] Facon, Thierry Karlin, Lionel Perrot, Aurore Podar, Klaus Kauffman, Michael G Shacham, Sharon Li, Lingling Tang, Shijie Picklesimer, Carla Saint-Martin, Jean-Richard Crochiere, Marsha Chang, Hua Parekh, Samir Landesman, Yosef Shah, Jatin Richardson, Paul G Jagannath, Sundar et al.[show all]

(eng) BACKGROUND: Selinexor, a selective inhibitor of nuclear export compound that blocks exportin 1 (XPO1) and forces nuclear accumulation and activation of tumor suppressor proteins, inhibits nuclear factor κB, and reduces oncoprotein messenger RNA translation, is a potential novel treatment for myeloma that is refractory to current therapeutic options. METHODS: We administered oral selinexor (80 mg) plus dexamethasone (20 mg) twice weekly to patients with myeloma who had previous exposure to bortezomib, carfilzomib, lenalidomide, pomalidomide, daratumumab, and an alkylating agent and had disease refractory to at least one proteasome inhibitor, one immunomodulatory agent, and daratumumab (triple-class refractory). The primary end point was overall response, defined as a partial response or better, with response assessed by an independent review committee. Clinical benefit, defined as a minimal response or better, was a secondary end point. RESULTS: A total of 122 patients in the United States and Europe were included in the modified intention-to-treat population (primary analysis), and 123 were included in the safety population. The median age was 65 years, and the median number of previous regimens was 7; a total of 53% of the patients had high-risk cytogenetic abnormalities. A partial response or better was observed in 26% of patients (95% confidence interval, 19 to 35), including two stringent complete responses; 39% of patients had a minimal response or better. The median duration of response was 4.4 months, median progression-free survival was 3.7 months, and median overall survival was 8.6 months. Fatigue, nausea, and decreased appetite were common and were typically grade 1 or 2 (grade 3 events were noted in up to 25% of patients, and no grade 4 events were reported). Thrombocytopenia occurred in 73% of the patients (grade 3 in 25% and grade 4 in 33%). Thrombocytopenia led to bleeding events of grade 3 or higher in 6 patients. CONCLUSIONS: Selinexor-dexamethasone resulted in objective treatment responses in patients with myeloma refractory to currently available therapies. (Funded by Karyopharm Therapeutics; STORM ClinicalTrials.gov number, NCT02336815.).